Wyeth formally opened its Grange Castle biotech production facility in South County Dublin, Ireland last week. The $2 Billion, 1.2 million square foot campus is one of the largest integrated biotech manufacturing facilities in the world and is expected to produce some of the Company's most innovative products.

During the opening, Wyeth Pharmaceuticals President Bernard Poussot said,

"The work performed in this facility will lead the way to better and more innovative healthcare through the application of biotechnology developed right here, in Ireland. We expect to continue to invest in this new state-of-the-art facility and to make Grange Castle one of our key biotech development, production and distribution efforts in the coming years, complementing our U.S. presence in Andover, Mass."

Biotech drugs are a rapidly growing segment of Wyeth's more than $17.4 billion business. Among the biotech products that will be produced at Grange Castle are:

• Enbrel, for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis.
  
• Prevenar, a pneumococcal vaccine for children, and
  
• Tygacil(TM), an intravenous antibiotic for the treatment of serious skin and intra-abdominal hospital acquired infections (on Phase 3 clinical trials).
• 
  
  Read Wyeth's press release here.